Jonathan McCone

5.9k total citations · 3 hit papers
20 papers, 3.7k citations indexed

About

Jonathan McCone is a scholar working on Hepatology, Epidemiology and Genetics. According to data from OpenAlex, Jonathan McCone has authored 20 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 12 papers in Epidemiology and 3 papers in Genetics. Recurrent topics in Jonathan McCone's work include Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (7 papers). Jonathan McCone is often cited by papers focused on Hepatitis C virus research (14 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (7 papers). Jonathan McCone collaborates with scholars based in United States, Canada and Italy. Jonathan McCone's co-authors include Clifford A. Brass, Janice K. Albrecht, Mark Sulkowski, Bruce R. Bacon, Ira M. Jacobson, Fred Poordad, K. Rajender Reddy, Navdeep Boparai, Michael P. Manns and Mark J. DiNubile and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Jonathan McCone

19 papers receiving 3.6k citations

Hit Papers

Boceprevir for Untreated Chronic HCV Genotype 1 Infection 2009 2026 2014 2020 2011 2009 2010 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
    2011 1.9k citations Fred Poordad, Jonathan McCone et al. New England Journal of Medicine profile →
  2. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
  3. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan McCone United States 12 3.5k 3.1k 700 355 164 20 3.7k
Peter Ferenci Austria 17 2.4k 0.7× 2.1k 0.7× 477 0.7× 259 0.7× 123 0.8× 41 2.6k
Vilma Sniukiene United States 15 2.3k 0.7× 2.0k 0.7× 510 0.7× 233 0.7× 108 0.7× 39 2.6k
Fernando Lopes Gonçales Brazil 15 5.7k 1.6× 5.0k 1.6× 757 1.1× 563 1.6× 260 1.6× 42 6.1k
Nicole Forestier Germany 19 2.3k 0.6× 1.9k 0.6× 704 1.0× 239 0.7× 441 2.7× 38 3.0k
Nathalie Adda United States 18 2.0k 0.6× 1.8k 0.6× 685 1.0× 181 0.5× 133 0.8× 55 2.3k
Shelley George United States 11 2.0k 0.6× 1.7k 0.6× 510 0.7× 232 0.7× 103 0.6× 32 2.1k
Hélène Fontaine France 23 3.0k 0.9× 3.2k 1.0× 339 0.5× 159 0.4× 312 1.9× 58 3.9k
Michiko Shindo Japan 24 2.1k 0.6× 1.9k 0.6× 152 0.2× 390 1.1× 125 0.8× 64 2.4k
Tatsuya Ide Japan 20 2.2k 0.6× 2.2k 0.7× 174 0.2× 178 0.5× 301 1.8× 120 2.9k
E. Del Ninno Italy 27 3.8k 1.1× 3.6k 1.2× 159 0.2× 182 0.5× 279 1.7× 74 4.6k

Countries citing papers authored by Jonathan McCone

Since Specialization
Citations

This map shows the geographic impact of Jonathan McCone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan McCone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan McCone more than expected).

Fields of papers citing papers by Jonathan McCone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan McCone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan McCone. The network helps show where Jonathan McCone may publish in the future.

Co-authorship network of co-authors of Jonathan McCone

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan McCone. A scholar is included among the top collaborators of Jonathan McCone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan McCone. Jonathan McCone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6. 31 indexed citations
2.
Vierling, John M., Mitchell Davis, Steven L. Flamm, et al.. (2012). 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results. Gastroenterology. 142(5). S–931. 2 indexed citations
3.
Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2011). PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY. Hepatology. 54.
4.
Melia, Michael T., Andrew J. Muir, Jonathan McCone, et al.. (2011). Racial differences in hepatitis C treatment eligibility. Hepatology. 54(1). 70–78. 36 indexed citations
5.
Poordad, Fred, Jonathan McCone, Bruce R. Bacon, et al.. (2011). Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 364(13). 1195–1206. 1888 indexed citations breakdown →
6.
Sulkowski, Mark, Mitchell L. Shiffman, Nezam H. Afdhal, et al.. (2010). Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. Gastroenterology. 139(5). 1602–1611.e1. 82 indexed citations
7.
Kwo, Paul Y., Eric Lawitz, Jonathan McCone, et al.. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet. 376(9742). 705–716. 515 indexed citations breakdown →
8.
Sulkowski, Mark, Stephen A. Harrison, Lorenzo Rossaro, et al.. (2010). Impaired Fasting Glucose Is Associated With Lower Rates of Sustained Virologic Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC): Retrospective Analysis of the IDEAL Study. 2 indexed citations
9.
Muir, Andrew J., Ke-Qin Hu, Stuart C. Gordon, et al.. (2010). Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Journal of Viral Hepatitis. 18(4). e134–43. 23 indexed citations
10.
Poordad, F., Mark Sulkowski, John G. McHutchison, et al.. (2010). High Correlation Between Week 4 and Week 12 as the Definition for Null Response to Peginterferon alfa (PEG) Plus Ribavirin (R) Therapy: Results From the IDEAL Trial. 3 indexed citations
11.
Vierling, John M., Robert Ralston, E.J. Lawitz, et al.. (2010). 2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1). Journal of Hepatology. 52. S470–S471. 21 indexed citations
12.
Sulkowski, Mark, M. Shiffman, Jonathan McCone, et al.. (2009). 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY. Journal of Hepatology. 50. S51–S52. 3 indexed citations
13.
McHutchison, John G., Eric Lawitz, Mitchell L. Shiffman, et al.. (2009). Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New England Journal of Medicine. 361(6). 580–593. 889 indexed citations breakdown →
14.
15.
16.
Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371. 29 indexed citations
17.
Poordad, Fred, Norbert Bräu, Eric Lawitz, et al.. (2008). Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin. 1 indexed citations
18.
Kwo, Paul Y., E. Läwitz, Jonathan McCone, et al.. (2008). 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC. Journal of Hepatology. 48. S372–S372. 31 indexed citations
19.
Jacobson, Ira M., Robert S. Brown, Jonathan McCone, et al.. (2007). Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. Hepatology. 46(4). 982–990. 55 indexed citations
20.
Cotler, Scott J., Teresa Craft, Mary W. Ferris, et al.. (2002). Induction of IL-1Ra in Resistant and Responsive Hepatitis C Patients Following Treatment with IFN-con1. Journal of Interferon & Cytokine Research. 22(5). 549–554. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Ferenci Breakdown of academic impact, for papers by Vilma Sniukiene Breakdown of academic impact, for papers by Fernando Lopes Gonçales Breakdown of academic impact, for papers by Nicole Forestier Breakdown of academic impact, for papers by Nathalie Adda Breakdown of academic impact, for papers by Shelley George Breakdown of academic impact, for papers by Hélène Fontaine Breakdown of academic impact, for papers by Michiko Shindo Breakdown of academic impact, for papers by Tatsuya Ide Breakdown of academic impact, for papers by E. Del Ninno
Rankless by CCL
2026